Carbonic anhydrases and tumor hypoxia.
In solid tumors vasculature is poor and limits the blood supply to the tumor mass, this in turn reduces the delivery of O 2 to tumor cells. Low O 2 , or hypoxia, induces the activation of the hypoxia-inducible transcription factor (HIF). 4 High levels of HIF regulate a signalling cascade involving ~100 genes that initiate adaptive cellular functions to allow solid tumor cells to survive hypoxia, to proliferate and to metastasize. 4 CA IX is one of the most highly induced HIF responsive genes and is overexpressed and sustained in a large number of solid tumors including breast, brain (glioblastoma), clear cell renal, colorectal, head and neck, bladder and non-small cell lung carcinomas, [5] [6] [7] yet CA IX has limited distribution and expression in normal tissues. [5] [6] [7] CA IX is a multidomain protein consisting of an N-terminal proteoglycan like domain, a transmembrane domain, a short intracellular domain and an extracellular catalytic domain. 8 Tumor cells experience elevated metabolism and thus increased acid production compared to healthy cells. 4, 9, 10 For some time it was thought that tumor cells had both a lower intracellular pH (pH i ) and extracellular pH (pH e ), however it became apparent from a number of studies that tumor cells actually maintain a normal pH i . 10 Tumour cells have evolved several mechanisms to extrude acid into the extracellular environment to counteract the acid load of elevated metabolism and these mechanisms contribute to lowering extracellular pH (pH e ) 10 which favours tumor invasive behaviour and development. 11 Recent evidence has demonstrated that cell-generated CO 2 in addition to lactic acid is responsible for the rapid removal of acid equivalents from tumor cells. 9, 12, 13 Cell-derived CO 2 is membrane permeable, so provided there is sufficient outward gradient this CO 2 diffuses to the extracellular space, where in poorly vascularised hypoxic tumor tissue, it is hydrated to HCO 3 -and a H + by CA IX (and/or CA XII). 9, 12, 13 The functional contribution of CAs to hypoxic tumor growth and progression has long been hypothesized; however recent convergent evidence from a number of groups strongly implicates these extracellular membrane-bound CAs are the key regulatory molecules for countering acidosis during hypoxia, Figure 1 . 9, [12] [13] [14] The net effect of CA IX/XII is to trap acid extracellularly, lowering extracellular pH (pH e ~6.9-7.0) and maintaining normal pH i (~7.2) with HCO 3 -recycled back into the cell. CAs in hypoxic tumours through pH i regulation. 
Sulfamate CA inhibitors
Solvay Pharmaceuticals GMBH filed an international patent application describing sulfamate compounds for medical use (treatment and/or prophylaxis) for a very broad range of health disorders, including obesity, diabetes mellitus type I and II, metabolic syndrome X, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, hypertension, asthma, glucose metabolism disorders, Parkinson's disease, Alzheimer's disease, arrhythmia, impotence, glaucoma, dipolar disorders, migraine, cardiovascular disease and cancer. 24 Sulfamates are isosteres of sulfonamides, wherein the sulfonamide sulphur atom is attached to an electronegative oxygen atom with the general formula R-O-SO 2 NH 2 and can bind to the active site Zn 2+ similarly to Figure 2 . Topiramate, a fructopyranose sulfamate, is a billion dollar drug that is marketed worldwide for the treatment of epilepsy and migraine. 25 This compound has been shown to be a good inhibitor of CAs in vitro by the CO 2 hydration assay. 26 Since this finding a number of sulfamates with excellent CA inhibition have been reported in the literature. 27 This patent application describes the synthesis of sulfamates of the general structure 124 (for CA inhibition R 1 = R 2 = H). Compounds contain one or more asymmetric centres, and a representative structure from this application is compound 125. The sulfamates are synthesized by the reaction of a primary alcohol with sulfamoyl chloride, this being well established chemistry. 28 The compounds of this invention are reported to have CA I, II and VB inhibition activity, with inhibition determined using a fluorescence based assay in which compounds are assessed for their ability to displace the fluorescent sulfonamide ligand, 5- This patent application claims the compounds of type 126 have improved CA isozyme selectivity than the standard CA inhibitors. The validity of this claim in the absence of inhibition data against all catalytically active human CA isozymes is questionable. Of particular relevance to this review is that studies of the compounds with the cancer-associated CA isozymes were neither presented nor discussed.
CA IX inhibitors as radiopharmaceuticals -1.
Siemens Medical Solutions USA, Inc. has filed a world patent application describing the parallel synthesis of CA inhibitors using click chemistry, and the subsequent synthesis and use of selected inhibitors as positron emission tomography (PET) imaging agents. 31 The application is based on the use of CA IX inhibitors in PET to identify and monitor CA IX expression in vivo and to predict the likely efficacy of CA IX inhibitors administered as a therapy to treat disease associated with the overexpression of CA IX, such as hypoxic cancers.
The background to this application is the association of CA IX expression with hypoxic tumors and hence the biomarker potential of this CA isozyme in cancer diagnostics.
Highlighted as of particular interest were cancers of the breast, gastrointestinal tract, stomach (including esophagus), colon, kidney, prostate, liver, urinary tract (including bladder), lungs, head and neck, and gynaecological cancers.
The concept of the 'tail approach' for developing selective CA inhibitors was first described by Supuran and co-workers. 32 Since this initial report the linking of an aromatic or heteroaromatic sulfonamide scaffold to a 'tail' group has proven a reliable means to alter the physicochemical properties of CA inhibitors. The linking of the 'tail' moiety has been achieved using myriad synthetic chemistry reactions including click chemistry, cross metathesis, amide, ester, urea, thiourea, sulfonamide etc. 17, [33] [34] [35] This patent application describes the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction of organic azides with terminal alkyne moieties (i.e. click chemistry) for the formation of a 1,2,3-triazole as the covalent linkage. This "click tailing" approach has been described by others previously. 33 Compounds 127-129 represent exemplary CA inhibition scaffolds from this application.
These scaffolds have both the primary sulfonamide moiety needed for CA inhibition and the alkyne moiety needed to participate in click chemistry. 
CA IX inhibitors as radiopharmaceuticals -2.
Molecular Insight Pharmaceuticals, Inc. is a company that focuses on the discovery and development of radiopharmaceuticals for use in oncology. The company has filed a world patent application describing the design, synthesis and administration of CA inhibitors as radiopharmaceuticals for use in cancer diagnostic imaging and as a radiotherapy. 36 The basis 
Summary
In summary, the 2007-2009 patent application activity surrounding therapeutic applications of small molecule CA inhibitors in oncology have been filed by both small-mid sized pharmaceutical companies and academia, with Big Pharma applicants noticeably absent.
These applications incorporate either classical chemotherapeutic or radiotherpeutic end use for cancer. The small molecules all contain a zinc binding function -sulfonamide or sulfamate -to ensure CA active site recognition and inhibition, while novelty of structure is found elsewhere in the molecules. A variety of different in vitro enzyme assays were employed to study the binding interactions with CA enzymes, including the CO 2 hydration assay method, the CA-esterase activity assay, the fluorescence based displacement assay, ITC and a fluorescent thermal shift assay. There were no in vivo results presented to confirm the therapeutic claims regarding the effect of these inhibitors in oncology.
Expert opinion
There is an immense sense of urgency for the development of new cancer therapies owing to the 1.5 million individuals diagnosed with and the 500,000 who die of cancer each year. 37 New molecular entities and biologic licence applications approved by the US Food and Drug
Administrations Center for Drug Evaluation and Research associated with oncology are desperately needed, with just five new cancer related approvals in 2010. 38 We are now in an exciting era in which there is great potential to develop rational, hypothesis-driven, mechanism-based molecular therapeutics for cancer. 39 CAs haves a brilliant track record as a model enzyme for countless studies across numerous scientific disciplines. 3 It has been shown recently that cancer-associated CAs (isozymes IX an XII) are a pivotal response for hypoxic cancer cell survival and proliferation. and DMPK (drug metabolism and pharmacokinetics) properties. The patent applications in the radiopharmaceutical area are thus quite interesting and the followup on these patents including the in vivo and/or clinical performance of these compounds is earnestly awaited.
The patent applications utilise a cross section of in vitro CA assay methods, however only one of these methods, the CO 2 hydration method, confirms CA inhibition activity. Other assay methods are technically easier to carry out, however they provide the field with inconsistencies. Drug discovery around CA inhibition will necessitate at some point that the endogenous activity of the CA enzyme be evaluated in the presence of an inhibitor, and a move away from indirect assays to the CO 2 hydration method is warranted.
Given the active site similarities of the 12 catalytically active human CAs, 3 CAs are a challenging drug target. It would be useful for researchers to have comprehensive CA inhibition data across all CA isozymes. At the very least small molecule inhibitors should be assessed at the physiologically dominant CA I and II as well as the cancer-associated CA IX and XII. To transform a small molecule inhibitor into a medicine that can be used in people requires conquering a spectrum of challenges and the physicochemical and toxicological properties that make a compound drug-like and safe must be considered alongside the goal to deliver compounds with desirable enzyme activity and selectivity. The CA field should commence with earnest to address drug like ADME and DMPK properties at the outset, in particular the evaluation of general toxicity needs to become routine in order to identify this potential liability early. There is currently a heavy reliance on in vitro enzyme assay results, yet a compounds in vivo or clinical performance cannot be inferred from this. Finally, the CA active sites are extremely tolerant to diverse and variable structural characteristics within the tail moiety of small molecule inhibitors. Provided there is a suitable zinc binding group such as sulfonamide or sulfamate, inhibitor tail groups may vary considerable in size, shape, charge, polarity, hydrophobicity etc. and yet still give nM inhibition. This minimal structural requirement in principle could permit an inhibitor design and development strategy that focuses less on optimizing structure-activity relationships (SAR) and more on finetuning the biopharmaceutical and toxicological properties of the inhibitor through structural manipulations. This attention towards optimizing structure-property relationships (SPR) may more rapidly guide this field towards drug discovery.
Article highlights box
• It has been shown recently that cancer-associated carbonic anhydrases (isozymes IX an XII) are a pivotal prosurvival enzymes during tumour hypoxia by regulating intracellular pH.
• Using shRNA gene silencing technology in a transfected LS174T colorectal cancer xenograft models ca9 and ca12 gene silencing caused a dramatic 85% reduction in tumor volume.
• The CA field has until recently lacked CA-relevant cell and animal models of tumor hypoxia for the therapeutic evaluation of small molecules. Verification of the ability of small molecules to modulate CA activity as a cancer therapy is however now possible with these models.
• CA inhibition is a new mechanism of action in oncology and small molecule inhibitors are under development as both classical chemotherapies for treatment and as radiopharmaceuticals for diagnostics and monitoring. 
